Payment overview · 2025
General Payments
$43.30
2 reported records · 2 companies
Healthcare provider profile · identity verified
Jon W Kroeze, MD
Allopathic & Osteopathic Physicians|Family Medicine · HOLLAND, MI · NPI 1053405548
Verified facts
What the public records show
CMS Open Payments records show Jon W Kroeze, MD received $43.30 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 54.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.61 | 54.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.69 | 45.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $43.30 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
48 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 290 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 281 | 70 |
| Losartan Potassium | Losartan Potassium | 260 | 71 |
| Irbesartan | Irbesartan | 244 | 57 |
| Omeprazole | Omeprazole | 213 | 59 |
| Lisinopril | Lisinopril | 193 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 162 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 44 |
| Alprazolam | Alprazolam | 142 | 43 |
| Meloxicam | Meloxicam | 128 | 34 |
| Famotidine | Famotidine | 124 | 25 |
| Metformin Hcl | Metformin Hcl | 124 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 30 |
| Metformin Hcl Er | Metformin Hcl | 113 | 33 |
| Montelukast Sodium | Montelukast Sodium | 105 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 24 |
| Pregabalin | Pregabalin | 102 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 29 |
| Gabapentin | Gabapentin | 97 | 31 |
| Simvastatin | Simvastatin | 95 | 24 |
| Potassium Chloride | Potassium Chloride | 90 | 25 |
| Trazodone Hcl | Trazodone Hcl | 90 | 20 |
| Tramadol Hcl | Tramadol Hcl | 87 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 80 | 19 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 74 | 14 |
| Furosemide | Furosemide | 72 | 26 |
| Sertraline Hcl | Sertraline Hcl | 71 | 18 |
| Eliquis | Apixaban | 68 | 14 |
| Bupropion Xl | Bupropion Hcl | 67 | 15 |
| Allopurinol | Allopurinol | 65 | 17 |
| Donepezil Hcl | Donepezil Hcl | 63 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 14 |
| Clonazepam | Clonazepam | 60 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 15 |
| Carvedilol | Carvedilol | 53 | 14 |
| Repaglinide | Repaglinide | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | suppressed |
| Jardiance | Empagliflozin | 50 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 15 |
| Chlorthalidone | Chlorthalidone | 49 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 48 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 47 | 43 |
| Warfarin Sodium | Warfarin Sodium | 44 | 11 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 43 | 43 |
| Lovastatin | Lovastatin | 43 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 40 | suppressed |
| Estradiol | Estradiol | 39 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Prednisone | Prednisone | 34 | 22 |
| Meclizine Hcl | Meclizine Hcl | 33 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 27 |
| Lorazepam | Lorazepam | 30 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 18 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 14 |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 21 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Nadolol | Nadolol | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Benzonatate | Benzonatate | 13 | 11 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Baclofen | Baclofen | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $43.30 · 2 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, PREVNAR 20, TRUMENBA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error